Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | MAP3K14 | Q99558 | 15/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16517440 | 0.86 | SCN9A (0.57) | SCN9AMAP3K14 | |
| SCHEMBL16516438 | 0.83 | MAP3K14 (0.56) | SCN9AMAP3K14RAB9ASMN1; SMN2 | |
| SCHEMBL16532434 | 0.80 | MAP3K14 (0.45) | SCN9AMAP3K14 | |
| SCHEMBL16517361 | 0.79 | MAP3K14 (0.47) | SCN9AMAP3K14RAB9ASMN1; SMN2 | |
| SCHEMBL16516996 | 0.77 | MAP3K14 (0.57) | SCN9AMAP3K14RAB9ASMN1; SMN2 | |
| SCHEMBL28079236 | 0.76 | ESR1 (0.37) | GAASMN1; SMN2 | |
| SCHEMBL16516433 | 0.75 | MAP3K14 (0.63) | GAASCN9AMAP3K14SMN1; SMN2 | |
| SCHEMBL16516700 | 0.74 | STAT1 (0.49) | SCN9AMAP3K14 | |
| SCHEMBL16517529 | 0.73 | MAP3K14 (0.65) | MAP3K14 | |
| SCHEMBL16517030 | 0.73 | MAP3K14 (0.55) | GAAMAP3K14KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (CA) | 2016-07-14 | — | — | US | disclosed |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (CA) | 2016-07-14 | — | — | US | disclosed |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (CA) | 2016-07-14 | — | — | US | disclosed |
| EP-3036230-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| CN-105658640-A | Alkynyl alcohols and methods of use | 豪夫迈·罗氏有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2015025025-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015025025-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | GAA 1695/4885SCN9A 760/4885MAP3K14 514/4885 |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | GAA 1695/4885SCN9A 760/4885MAP3K14 514/4885 |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | GAA 1695/4885SCN9A 760/4885MAP3K14 514/4885 |
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | GAA 1695/4885SCN9A 760/4885MAP3K14 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.